Association of lymphadenectomy and survival in stage I ovarian cancer patients

Obstetrics and Gynecology

Volumn 109, Issue 1, 2007, Pages 12-19

  Chan, John K ^a   Munro, Elizabeth G ^b   Cheung, Michael K ^b   Husain, Amreen ^b   Teng, Nelson N ^b   Berek, Jonathan S ^b   Osann, Kathryn ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AFRICAN AMERICAN; AGED; ARTICLE; ASIAN; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CAUCASIAN; CHILD; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; EPITHELIUM TUMOR; FEMALE; HISPANIC; HISTOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CANCER; PATHOLOGY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HEALTH STATUS; HUMANS; INFANT; KAPLAN-MEIERS ESTIMATE; LYMPH NODE EXCISION; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 33846001355     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000249610.95885.ef     Document Type: Article

References (26)

1. Kohler M, Janz I, Wintzer HO, Wagner E, Bauknecht T. The expression of EGF receptors, EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance. Anticancer Res 1989;9:1537-47.
2. DiSaia PJ, Creasman WT. Clinical gynecologic oncology. 6th ed. St. Louis (MO): Mosby; 2002.
3. FIGO Cancer Committee. Staging announcements. Gynecol Oncol 1986;25:383-5.
4. Chan AD, Essner R, Wanek LA, Morton DL. Judging the therapeutic value of lymph node dissections for melanoma. J Am Coll Surg 2000;191:16-22; discussion 22-3.
5. Krag DN, Single RM. Breast cancer survival according to number of nodes removed. Ann Surg Oncol 2003;10:1152-9.
6. Weir L, Speers C, D'Yachkova Y, Olivotto IA. Prognostic significance of the number of axillary lymph nodes removed in patients with node-negative breast cancer. J Clin Oncol 2002;20:1793-9.
7. Sosa JA, Diener-West M, Gusev Y, Choti MA, Lange JR, Dooley WC, et al. Association between extent of axillary lymph node dissection and survival in patients with stage I breast cancer. Ann Surg Oncol 1998;5:140-9.
8. Tepper JE, O'Connell MJ, Niedzwiecki D, Hollis D, Compton C, Benson III AB, et al. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol 2001;19:157-63.
9. McGowan L, Lesher LP, Norris HJ, Barnett M. Misstaging of ovarian cancer. Obstet Gynecol 1985;65:568-72.
10. Trimbos JB, Schueler JA, van Lent M, Hermans J, Fleuren GJ. Reasons for incomplete surgical staging in early ovarian carcinoma. Gynecol Oncol 1990;37:374-7.
11. Young RC, Decker DG, Wharton JT, Piver MS, Sindelar WF, Edwards BK, et al. Staging laparotomy in early ovarian cancer. JAMA 1983;250:3072-6.
12. Helewa ME, Krepart GV, Lotocki R. Staging laparotomy in early epithelial ovarian carcinoma. Am J Obstet Gynecol 1986;154:282-6.
13. Soper JT, Johnson P, Johnson V, Berchuck A, Clarke-Pearson DL. Comprehensive restaging laparotomy in women with apparent early ovarian carcinoma. Obstet Gynecol 1992;80:949-53.
14. Cass I, Li AJ, Runowicz CD, Fields AL, Goldberg GL, Leuchter RS, et al. Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas. Gynecol Oncol 2001;80:56-61.
15. Puls LE, Carrasco R, Morrow MS, Blackhurst D. Stage I ovarian carcinoma: specialty-related differences in survival and management. South Med J 1997;90:1097-100.
16. Zanetta G, Rota S, Chiari S, Bonazzi C, Bratina G, Torri V, et al. The accuracy of staging: an important prognostic determinator in stage I ovarian carcinoma. A multivariate analysis. Ann Oncol 1998;9:1097-101.
17. Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer: results of two prospective randomized trials. N Engl J Med 1990;322:1021-7.
18. Sonoda Y. Management of early ovarian cancer. Oncology (Williston Park) 2004;18:343-56; discussion 358, 361-2.
19. Mandell RB, Mandell LZ, Link CJ Jr. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 1999;59:661-8.
20. Girardi F, Petru E, Heydarfadai M, Haas J, Winter R. Pelvic lymphadenectomy in the surgical treatment of endometrial cancer. Gynecol Oncol 1993;49:177-80.
21. Morice P, Joulie F, Camatte S, Atallah D, Rouzier R, Pautier P, et al. Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg 2003;197:198-205.
22. Cress RD, O'Malley CD, Leiserowitz GS, Campleman SL. Patterns of chemotherapy use for women with ovarian cancer: a population-based study. J Clin Oncol 2003;21:1530-5.
23. Petignat P, Vajda D, Joris F, Obrist R. Surgical management of epithelial ovarian cancer at community hospitals: a population-based study. J Surg Oncol 2000;75:19-23.
24. Hankey BF, Ries LA, Edwards BK. The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomarkers Prev 1999;8:1117-21.
25. Virnig BA, Warren JL, Cooper GS, Klabunde CN, Schussler N, Freeman J. Studying radiation therapy using SEER-Medicare-linked data. Med Care 2002;40 suppl:IV-49-54.
26. Cooper GS, Virnig B, Klabunde CN, Schussler N, Freeman J, Warren JL. Use of SEER-Medicare data for measuring cancer surgery. Med Care 2002;40 suppl:IV- 43-8.